Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 51

Sort by

Sort Order Select

Journal Articles

Mutation Spectrum, Characteristics and Impact of Mutation Profiling on Prognosis, Outcome and Treatment Responses in Patients (pts) with Mantle Cell Lymphoma

Blood (2022) 140 (Supplement 1): 3598–3600.

https://doi.org/10.1182/blood-2022-162806

Published: 2022

Journal Articles

Combined Structural Variant and Mutation Profiling for Comprehensive Characterization of Chromoanagenesis and TP53 Mutations in Myelodysplastic Syndromes with Complex Karyotype

Hui Yang, Guillermo Garcia-Manero, Yue Wei, Koji Sasaki, Kelly S. Chien, Zhenya Tang, Guillermo Montalban-Bravo, Awdesh Kalia, Rajyalakshmi Luthra, L. Jeffrey Medeiros, Rashmi Kanagal-Shamanna

Blood (2022) 140 (Supplement 1): 7844–7845.

https://doi.org/10.1182/blood-2022-171152

Published: 2022

Journal Articles

Homologous Recombination DNA Repair Deficiency Score Is Independent Prognostic Variable in Myelodysplastic Syndrome/ Acute Myeloid Leukemia with Complex Karyotype

Ha Nguyen, Koji Sasaki, Farhad Ravandi, Rajyalakshmi Luthra, Keyur P. Patel, Sanam Loghavi, Fatima Zahra Jelloul, Mark Routbort, Awdesh Kalia, Guillermo Montalban-Bravo, Kelly S. Chien, Peter Hu, Musa Yilmaz, Carlos E. Bueso-Ramos, L. Jeffrey Medeiros, Guillermo Garcia-Manero, Rashmi Kanagal-Shamanna

Blood (2022) 140 (Supplement 1): 1353–1354.

https://doi.org/10.1182/blood-2022-168999

Published: 2022

Journal Articles

High-Throughput Characterization of Cytogenomic Heterogeneity of MDS Using High-Resolution Optical Genome Mapping

Hui Yang, Guillermo Garcia-Manero, Guillermo Montalban-Bravo, Kelly S. Chien, Awdesh Kalia, Zhenya Tang, Yue Wei, Manjunath Nimmakayalu, Diana Rush, Saradhi Mallampati, Hagop Kantarjian, Rajyalakshmi Luthra, L. Jeffrey Medeiros, Rashmi Kanagal-Shamanna

Blood (2021) 138 (Supplement 1): 105.

https://doi.org/10.1182/blood-2021-154005

Published: 2021

Journal Articles

Distinct Prognostic Effects of TP53 Mutations in Newly Diagnosed Versus Relapsed/Refractory (R-R) Patients (pts) with B-Acute Lymphoblastic Leukemia (ALL) Treated with Mini-Hcvd-Inotuzumab Ozogamicin with or without Blinatumomab Regimens

Rashmi Kanagal-Shamanna, MD, Hagop M. Kantarjian, MD, Joseph D. Khoury, MD, Koichi Takahashi, MD PhD, Guillermo Montalban-Bravo, MD, Nicholas J. Short, MD, C. Cameron Yin, MD PhD, Keyur Patel, MD PhD, Sanam Loghavi, MD, Farhad Ravandi, MBBS, Marina Konopleva, MD PhD, Nitin Jain, MD, Guillermo Garcia-Manero, MD, Naval Daver, MD, Tapan M. Kadia, MD, Courtney D. DiNardo, MD MSCE, Susan M. O'Brien, MD, Rajyalakshmi Luthra, PhD, Elias Jabbour, MD

Blood (2020) 136 (Supplement 1): 41–43.

https://doi.org/10.1182/blood-2020-142012

Published: 2020

Journal Articles

Evolutionary Action Score Identifies a Subset of TP53 Mutated Myelodysplastic Syndrome with Favorable Prognosis

Blood (2020) 136 (Supplement 1): 4–5.

https://doi.org/10.1182/blood-2020-141411

Published: 2020

Journal Articles

High-Resolution Next-Generation Whole Genome Optical Mapping As a Novel Molecular Diagnostic Tool for Comprehensive Assessment of Structural Chromosomal Variations in Myelodysplastic Syndromes

Rashmi Kanagal-Shamanna, MD, Guillermo Montalban-Bravo, MD, Koji Sasaki, MD, Rajyalakshmi Luthra, PhD, Hui Yang, PhDMD, Gokce A. Toruner, MD PhD, Keyur P. Patel, MBBS, PhD, Saradhi Mallampati, DVM, PhD, Hagop M. Kantarjian, MD, Carlos E. Bueso-Ramos, MD PhD, L. Jeffrey Medeiros, MD, Guillermo Garcia-Manero, MD

Blood (2019) 134 (Supplement_1): 5438.

https://doi.org/10.1182/blood-2019-131971

Published: 2019

Journal Articles

A phase 2 study of ruxolitinib in combination with azacitidine in patients with myelofibrosis

Blood (2018) 132 (16): 1664–1674.

https://doi.org/10.1182/blood-2018-04-846626

Published: 2018

Includes: Supplemental data

Journal Articles

Absolute Percent Deviation of IGHV Mutation As a Continuum Is Prognostically Relevant in Patients with CLL

Preetesh Jain, MBBS,MDDM,PhD, Jan A. Burger, MD PhD, Graciela Nogueras González, Rashmi Kanagal-Shamanna, MD, Uri Rozovski, MD, Constantine S. Tam, MBBS, MD FRACP, FRCPA, William G Wierda, MD PhD, Philip A Thompson, MBBS, Nawid Sarwari, MD, Rajyalakshmi Luthra, PhD, Andrew Quesada, Nitin Jain, MD, Alessandra Ferrajoli, MD, Hagop M. Kantarjian, MD, Jorge E. Cortes, MD, Susan M. O'Brien, MD, Michael J. Keating, MD, Zeev Estrov, MD

Blood (2017) 130 (Supplement 1): 3006.

https://doi.org/10.1182/blood.V130.Suppl_1.3006.3006

Published: 2017

Journal Articles

Endleukemia Assay v1: Enabling NGS-Based Comprehensive Routine Molecular Profiling of Leukemias in Routine Clinical Care

Chi Young Ok, MD, Rajesh Singh, PhD, Rajyalakshmi Luthra, PhD, David Hatfield, Kristen Floyd, Sanam Loghavi, MD, Rashmi Kanagal-Shamanna, MD, Zhuang Zuo, C. Cameron Yin, MD PhD, Mark Routbort, MD PhD, Hagop M. Kantarjian, MD, L. Jeffrey Medeiros, MD, Keyur P. Patel, MBBS, PhD

Blood (2017) 130 (Supplement 1): 2679.

https://doi.org/10.1182/blood.V130.Suppl_1.2679.2679

Published: 2017

Journal Articles

Clonal evolution and outcomes in myelofibrosis after ruxolitinib discontinuation

Kate J. Newberry, Keyur Patel, Lucia Masarova, Rajyalakshmi Luthra, Taghi Manshouri, Elias Jabbour, Prithviraj Bose, Naval Daver, Jorge Cortes, Hagop Kantarjian, Srdan Verstovsek

Blood (2017) 130 (9): 1125–1131.

https://doi.org/10.1182/blood-2017-05-783225

Published: 2017

Includes: Supplemental data

Journal Articles

Long-term outcome of acute promyelocytic leukemia treated with all- trans -retinoic acid, arsenic trioxide, and gemtuzumab

Blood (2017) 129 (10): 1275–1283.

https://doi.org/10.1182/blood-2016-09-736686

Published: 2017

Journal Articles

Impact of complete molecular response on survival in patients with Philadelphia chromosome–positive acute lymphoblastic leukemia

Nicholas J. Short, Elias Jabbour, Koji Sasaki, Keyur Patel, Susan M. O’Brien, Jorge E. Cortes, Rebecca Garris, Ghayas C. Issa, Guillermo Garcia-Manero, Rajyalakshmi Luthra, Deborah Thomas, Hagop Kantarjian, Farhad Ravandi

Blood (2016) 128 (4): 504–507.

https://doi.org/10.1182/blood-2016-03-707562

Published: 2016

Includes: Supplemental data

Journal Articles

Impact of BCR-ABL transcript type on outcome in patients with chronic-phase CML treated with tyrosine kinase inhibitors

Preetesh Jain, Hagop Kantarjian, Keyur P. Patel, Graciela Nogueras Gonzalez, Rajyalakshmi Luthra, Rashmi Kanagal Shamanna, Koji Sasaki, Elias Jabbour, Carlos Guillermo Romo, Tapan M. Kadia, Naveen Pemmaraju, Naval Daver, Gautam Borthakur, Zeev Estrov, Farhad Ravandi, Susan O’Brien, Jorge Cortes

Blood (2016) 127 (10): 1269–1275.

https://doi.org/10.1182/blood-2015-10-674242

Published: 2016

Includes: Supplemental data

Journal Articles

Correlation of mutation profile and response in patients with myelofibrosis treated with ruxolitinib

Keyur P. Patel, Kate J. Newberry, Rajyalakshmi Luthra, Elias Jabbour, Sherry Pierce, Jorge Cortes, Rajesh Singh, Meenakshi Mehrotra, Mark J. Routbort, Madan Luthra, Taghi Manshouri, Fabio P. Santos, Hagop Kantarjian, Srdan Verstovsek

Blood (2015) 126 (6): 790–797.

https://doi.org/10.1182/blood-2015-03-633404

Published: 2015

Includes: Supplemental data

Journal Articles

JAK2 p.V617F detection and allele burden measurement in peripheral blood and bone marrow aspirates in patients with myeloproliferative neoplasms

Koichi Takahashi, Keyur P. Patel, Hagop Kantarjian, Rajyalakshmi Luthra, Sherry Pierce, Jorge Cortes, Srdan Verstovsek

Blood (2013) 122 (23): 3784–3786.

https://doi.org/10.1182/blood-2013-07-515676

Published: 2013

Journal Articles

BCR-ABL Fusion Transcripts In Patients With Chronic Myeloid Leukemia In Chronic Phase (CML-CP): Experience With Ponatinib From MD Anderson Cancer Center

Preetesh Jain, MD, DM, PhD, Hagop M. Kantarjian, MD, Carlos Guillermo Romo, MD, Rajyalakshmi Luthra, PhD, Alfonso Quintas-Cardama, MD, Elias Jabbour, MD, Tapan M. Kadia, MD, Gautam Borthakur, MD, Marylou Cardenas-Turanzas, MD, Dr PH, Sherry Pierce, Farhad Ravandi, MBBS, Susan M. O'Brien, MD, Jorge E. Cortes, MD

Blood (2013) 122 (21): 2727.

https://doi.org/10.1182/blood.V122.21.2727.2727

Published: 2013

Journal Articles

Combination Chemotherapy With Tyrosine Kinase Inhibitors Can Overcome Bcr-Abl Mutations In Acute Lymphoblastic Leukemia Or Blast Crisis CML

Ohad Benjamini, MD, Hagop M Kantarjian, MD, Susan O'Brien, MD, Deborah Thomas, MD, Farhad Ravandi, MD, Preetesh Jain, MD, DM, PhD, Sherry Pierce, Gautam Borthakur, MBBS, Tapan M. Kadia, MD, Elias Jabbour, MD, Zeev Estrov, MD, Rajyalakshmi Luthra, Ph.D., Jorge E. Cortes, MD

Blood (2013) 122 (21): 2734.

https://doi.org/10.1182/blood.V122.21.2734.2734

Published: 2013

Journal Articles

Replacing Gemtuzumab Ozogamicin With Idarubicin In Frontline Fludarabine, Cytarabine and G-CSF Based Regimen Does Not Compromise Outcome In Core Binding Factor Acute Myelogenous Leukemia

Gautam Borthakur, MD, Jorge E. Cortes, MD, Farhad Ravandi, MD, Graciela Nogueras Gonzalez, Rajyalakshmi Luthra, PhD, Elias Jabbour, MD, Guillermo Garcia-Manero, MD, Tapan M. Kadia, MD, Joyce Bass, Mark Brandt, Hagop M. Kantarjian, MD

Blood (2013) 122 (21): 3971.

https://doi.org/10.1182/blood.V122.21.3971.3971

Published: 2013

Journal Articles

Clinical characteristics and outcomes of therapy-related chronic myelomonocytic leukemia

Koichi Takahashi, Naveen Pemmaraju, Paolo Strati, Graciela Nogueras-Gonzalez, Jing Ning, Carlos Bueso-Ramos, Rajyalakshmi Luthra, Sherry Pierce, Jorge Cortes, Hagop Kantarjian, Guillermo Garcia-Manero

Blood (2013) 122 (16): 2807–2811.

https://doi.org/10.1182/blood-2013-03-491399

Published: 2013

Includes: Supplemental data

NARROW

Mutation Spectrum, Characteristics and Impact of Mutation Profiling on Prognosis, Outcome and Treatment Responses in Patients (pts) with Mantle Cell Lymphoma

Combined Structural Variant and Mutation Profiling for Comprehensive Characterization of Chromoanagenesis and TP53 Mutations in Myelodysplastic Syndromes with Complex Karyotype

Homologous Recombination DNA Repair Deficiency Score Is Independent Prognostic Variable in Myelodysplastic Syndrome/ Acute Myeloid Leukemia with Complex Karyotype

High-Throughput Characterization of Cytogenomic Heterogeneity of MDS Using High-Resolution Optical Genome Mapping

Distinct Prognostic Effects of TP53 Mutations in Newly Diagnosed Versus Relapsed/Refractory (R-R) Patients (pts) with B-Acute Lymphoblastic Leukemia (ALL) Treated with Mini-Hcvd-Inotuzumab Ozogamicin with or without Blinatumomab Regimens

Evolutionary Action Score Identifies a Subset of TP53 Mutated Myelodysplastic Syndrome with Favorable Prognosis

High-Resolution Next-Generation Whole Genome Optical Mapping As a Novel Molecular Diagnostic Tool for Comprehensive Assessment of Structural Chromosomal Variations in Myelodysplastic Syndromes

A phase 2 study of ruxolitinib in combination with azacitidine in patients with myelofibrosis

Absolute Percent Deviation of IGHV Mutation As a Continuum Is Prognostically Relevant in Patients with CLL

Endleukemia Assay v1: Enabling NGS-Based Comprehensive Routine Molecular Profiling of Leukemias in Routine Clinical Care

Clonal evolution and outcomes in myelofibrosis after ruxolitinib discontinuation

Long-term outcome of acute promyelocytic leukemia treated with all- trans -retinoic acid, arsenic trioxide, and gemtuzumab

Impact of complete molecular response on survival in patients with Philadelphia chromosome–positive acute lymphoblastic leukemia

Impact of BCR-ABL transcript type on outcome in patients with chronic-phase CML treated with tyrosine kinase inhibitors

Correlation of mutation profile and response in patients with myelofibrosis treated with ruxolitinib

JAK2 p.V617F detection and allele burden measurement in peripheral blood and bone marrow aspirates in patients with myeloproliferative neoplasms

BCR-ABL Fusion Transcripts In Patients With Chronic Myeloid Leukemia In Chronic Phase (CML-CP): Experience With Ponatinib From MD Anderson Cancer Center

Combination Chemotherapy With Tyrosine Kinase Inhibitors Can Overcome Bcr-Abl Mutations In Acute Lymphoblastic Leukemia Or Blast Crisis CML

Replacing Gemtuzumab Ozogamicin With Idarubicin In Frontline Fludarabine, Cytarabine and G-CSF Based Regimen Does Not Compromise Outcome In Core Binding Factor Acute Myelogenous Leukemia

Clinical characteristics and outcomes of therapy-related chronic myelomonocytic leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only